HPV vaccination of immunocompromised hosts

S M Garland; J M L Brotherton; A B Moscicki; A M Kaufmann; M Stanley; N Bhatla; R Sankaranarayanan; S de Sanjosé; J M Palefsky; IPVS

doi:10.1016/j.pvr.2017.06.002

HPV vaccination of immunocompromised hosts

Papillomavirus Res. 2017 Dec:4:35-38. doi: 10.1016/j.pvr.2017.06.002. Epub 2017 Jun 3.

Authors

S M Garland¹, J M L Brotherton², A B Moscicki³, A M Kaufmann⁴, M Stanley⁵, N Bhatla⁶, R Sankaranarayanan⁷, S de Sanjosé⁸, J M Palefsky⁹; IPVS

Affiliations

¹ Department of Microbiology and Infectious Diseases, Royal Women's Hospital, 30 Flemington Road, Parkville 3052, Australia; Murdoch Childrens Research Institute, 50 Flemington Road, Parkville 3052, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Parkville 3052, Australia. Electronic address: [email protected].
² VCS Registries, Victorian Cytology Service, Level 6, 176 Wellington Parade, East Melbourne 3002, Australia; School of Population and Global Health, University of Melbourne, Parkville 3052, Australia. Electronic address: [email protected].
³ Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Ave. MDCC 22-432, MC:175217, Los Angeles, CA 90095, United States. Electronic address: [email protected].
⁴ Gynäkologische Tumorimmunologie, R. 4503 Gynäkologie, Charite-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany. Electronic address: [email protected].
⁵ Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, United Kingdom. Electronic address: [email protected].
⁶ Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: [email protected].
⁷ Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, World Health Organization, 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France. Electronic address: [email protected].
⁸ Cancer Epidemiology Research Programme, IDIBELL, CIBERESP, Institut Català d'Oncologia, Av. Gran Via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat, Spain. Electronic address: [email protected].
⁹ University of California, San Francisco, 513 Parnassus Ave Box 0654, San Francisco, CA 94143, United States. Electronic address: [email protected].

Abstract

It is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to national guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose regimen.

Keywords: HPV Guidelines; HPV related cancers; Human papillomavirus (HPV); Immunocompromised hosts; Vaccination.

MeSH terms

Adolescent
Child
Female
Guidelines as Topic
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / administration & dosage*
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / adverse effects
Humans
Immunocompromised Host*
Immunogenicity, Vaccine
Papillomavirus Infections / prevention & control
Papillomavirus Infections / virology
Papillomavirus Vaccines / administration & dosage*
Papillomavirus Vaccines / adverse effects
Vaccination / adverse effects*
Vaccination / methods

Substances

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Papillomavirus Vaccines

Grants and funding

001/WHO_/World Health Organization/International